Opinion
Video
Dean Elterman, MD, shares 3-year data on Zenflow Spring System for BPH
“We're now entering an era of new types of technologies to treat BPH in a minimally invasive fashion,” says Dean Elterman, MD.
Three-year data from the ZEST pilot studies continued to show significant and durable benefit of the investigational Zenflow Spring System in patients with benign-prostatic hyperplasia (BPH).1
These data were shared during the 2025 American Urological Association (AUA) Annual Meeting in Las Vegas, Nevada. In an interview with Urology Times®, Dean Elterman, MD, a urologist at the University of Toronto in Canada, discussed the background and key findings from the study.
“We're now entering an era of new types of technologies to treat BPH in a minimally invasive fashion,” explained Elterman. “One of the concepts is this idea of first-line interventional therapies, which are essentially stent-like devices that are designed to be minimally invasive with respect to being inserted with a flexible scope. They can be done under local anesthesia. They provide benefit with respect to symptom improvement, but also preservation of sexual function, and they can be easily removed and reversed to allow patients to move on to other types of therapy. The Zenflow Spring System is essentially one of these FITs, or first-line intervention therapies.”
Elterman noted, “The main takeaways were, essentially, over 3 years, we saw a good, sustained improvement in symptom score measured by the IPSS; it improved up to 46%. We saw an improvement in quality of life by at least 50%. We saw an improvement in urinary peak flows by over 30%. We saw a great responder rate of around 74% of patients.”
Data also showed no deterioration in erectile or ejaculatory function over 36 months.
The Zenflow Spring System is currently being assessed in the prospective, randomized BREEZE trial (NCT04987138), which enrolled participants through clinical trial sites in the US and Canada.2
REFERENCES
1. Elterman D, Gilling P, Chin P, et al. 36-month outcomes from the ZEST pilot studies of the Zenflow Spring System for the treatment of benign prostatic hyperplasia (BPH). J Urol. 2025;213(5S):e277. doi:10.1097/01.JU.0001109800.53897.68.12
2. Safety and effectiveness study of the Zenflow Spring System (BREEZE). ClinicalTrials.gov. Last updated April 11, 2024. Accessed May 27, 2025. https://clinicaltrials.gov/study/NCT04987138
